Item 2.02 Results of Operations and Financial Condition.

Ocular Therapeutix, Inc. (the "Company") intends to present a Company overview at a virtual conference on January 11, 2021. Information to be provided during such presentation is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The Company primarily derives its product revenues from the sale of DEXTENZA® in the United States to a network of specialty distributors, who then resell DEXTENZA to ambulatory surgical centers ("ASCs") and hospital outpatient departments ("HOPDs"). The Company refers to these resales from the specialty distributors to the ASCs and HOPDs as in-market unit sales. Although the Company is currently in the process of finalizing its operational and financial results for the quarter ended December 31, 2020, the Company is reporting estimated in-market unit sales for DEXTENZA of 5,952 billable inserts in the month of December 2020. In-market unit sales were 4,198 billable inserts for October 2020 and 4,327 billable inserts for November 2020.

The estimated unit sales discussed above are based on preliminary information and management's estimates as of the date of this Current Report on Form 8-K and are subject to completion of the Company's customary closing procedures. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the estimated figures.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall be deemed to be "furnished" and not "filed" under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed to be incorporated by reference in applicable filings under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

The information set forth in or incorporated by reference into Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 7.01.

Item 9.01 Financial Statements and Exhibits.






 (d) Exhibits:




    99.1     Ocular Therapeutix, Inc. slide presentation, dated January 2021

           Cover Page Interactive Data File (embedded within the Inline XBRL
  104      document)

© Edgar Online, source Glimpses